Skip to main content
. 2023 Jun 5;2023(6):CD014915. doi: 10.1002/14651858.CD014915.pub2

1.1. Analysis.

1.1

Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 1: Patient Global Impression of Change (PGIC) of much improved or very much improved